Antimicrobial Susceptibility Testing Now Available for Tedizolid
New compound expands treatment options for serious skin infections, including MRSA
We’re pleased to be the first to offer susceptibility testing for tedizolid to microbiology labs worldwide as part of our expanding range of antimicrobials, and to be able to provide one of the latest testing options for resistant skin infections.

OAKWOOD VILLAGE, Ohio.--()--The antimicrobial tedizolid is now available on FDA-cleared microbroth dilution susceptibility plates, enabling microbiology labs to perform tedizolid susceptibility testing of fastidious and non-fastidious Gram positive organisms that cause acute bacterial skin and skin structure infections (ABSSSIs) in adults.

The Thermo Scientific Sensititre ID/AST System is the first to offer tedizolid on IVD-labeled, microbroth dilution susceptibility plates. Tedizolid is available on Sensititre custom plates, along with more than 240 other antimicrobial options, and it will be featured on new standard plates in the future. Testing can be performed manually, as well as using the Sensititre Vizion Digital MIC Viewing System, Sensititre OptiRead Automated Fluorometric Plate Reading System, or the fully automated Sensititre ARIS 2X System.

According to Finn Albrechtsen, vice president of R&D and business development, Thermo Fisher Scientific microbiology, “We’re pleased to be the first to offer susceptibility testing for tedizolid to microbiology labs worldwide as part of our expanding range of antimicrobials, and to be able to provide one of the latest testing options for resistant skin infections.”

The Sensititre System utilizes true minimum inhibitory concentration (MIC) results, which are essential to understanding antimicrobial resistance, providing greater sensitivity for better resistance tracking. True MIC results are also the preferred measure of antibacterial effect, which can assist with therapeutic choices, and promote overall better patient care.

Sivextro® (tedizolid phosphate) is approved by the FDA for the treatment of adults with ABSSSI caused by susceptible isolates of the following Gram positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenesStreptococcus agalactiaeStreptococcus anginosus group (including Streptococcus anginosusStreptococcus intermedius and Streptococcus constellatus), and Enterococcus faecalis.

More information on the Thermo Scientific Sensititre System can be found here, by visiting www.thermoscientific.com, or by contacting microbiology@thermofisher.com.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

 

Contacts

Thermo Fisher
Carlene Graham, 800-871-8909 x3224109
carlene.graham@thermofisher.com